| Species |
Human |
| Protein Construction |
TGFBR1 (Leu34-Glu125)
Accession # P36897-1 |
mFc (IgG1) |
Avi |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
38.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 50-55 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
transforming growth factor beta receptor 1 (TGFBR1), a key stimulator of tumor proliferation and metastasis, was a direct target of miR‑98‑5p. miR‑98‑5p overexpression resulted in the downregulation of TGFBR1 and the suppression of the viability, proliferation, migration and invasion of A549 and H1299 cells. |
| Synonyms |
AAT5; ACVRLK4; ALK-5; ALK5; LDS1A; LDS2A; SKR4; tbetaR-I; TGFB1R1; TGF-beta RI; TGFbetaRI; TGFBR1; TGF-bRI; TGFR-1; tβR-I; TGF-β RI; TGFβRI |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
